Shares of Gujarat Themis Biosyn surged 14.3% after the company announced an Asset Purchase Agreement with French pharmaceutical giant Sanofi to acquire a portfolio of 13 established branded generic anti-tuberculosis and anti-infective products for €158 million (approximately $170 million USD). The stock reached an intra-day high of ₹369.4 per share, while the broader BSE Sensex index fell by 1.25%. The acquired portfolio, which reported net sales of about €62 million for the year ending 2025, is present in over 55 countries across Europe, the Middle East, and Africa. This acquisition is part of Gujarat Themis's strategy to enhance its global footprint and leverage its existing capabilities in fermentation-based products to drive improved revenues and operational efficiency. The deal is expected to close by December 2026, subject to necessary regulatory approvals. Managing Director Sachin Patel emphasized that this acquisition represents a strategic milestone, enhancing the company's high-margin, fermentation-based pharmaceutical platform and reinforcing its leadership in the industry.